- Hepatocyte growth factor activation inhibitors - therapeutic potential in cancer. Parr, C., Sanders, A.J., Jiang, W.G. Anticancer. Agents. Med. Chem (2010)
- Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Parr, C., Sanders, A.J., Davies, G., Martin, T., Lane, J., Mason, M.D., Mansel, R.E., Jiang, W.G. Clin. Cancer Res. (2007)
- Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Parr, C., Jiang, W.G. Int. J. Cancer (2006)
- Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Parr, C., Gan, C.H., Watkins, G., Jiang, W.G. Angiogenesis (2006)
- Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Parr, C., Watkins, G., Boulton, M., Cai, J., Jiang, W.G. Eur. J. Cancer (2005)
- The hepatocyte growth factor regulatory factors in human breast cancer. Parr, C., Watkins, G., Mansel, R.E., Jiang, W.G. Clin. Cancer Res. (2004)
- The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Parr, C., Watkins, G., Jiang, W.G. Int. J. Mol. Med. (2004)
- Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Parr, C., Jiang, W.G. Int. J. Oncol. (2003)
- Hepatocyte growth factor activators, inhibitors and antagonists and their implication in cancer intervention. Parr, C., Jiang, W.G. Histol. Histopathol. (2001)
- Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Parr, C., Hiscox, S., Nakamura, T., Matsumoto, K., Jiang, W.G. Int. J. Cancer (2000)